ABC
AmerisourceBergen CorporationNYSE
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Mon, Nov. 21, 9:29 AM
    • Evercore ISI's Ross Muken says drug wholesalers AmerisourceBergen (NYSE:ABC) and McKesson are in the midst of a price war, stoked by an unfavorable image from ABC's customers, although he says ABC is holding its own against the threat. He doesn't see a further erosion in margins from either firm.
    • Competitor Cardinal Health (NYSE:CAH) appears to have sidestepped the tussle thus far.
    • All three stocks are quiet premarket.
    | Mon, Nov. 21, 9:29 AM | 1 Comment
  • Mon, Nov. 14, 4:42 PM
    • New positions for Greenlight Capital as of Sept. 30: U.S. Steel (NYSE:X), and GEO Group (NYSE:GEO).
    • Major exits: Twenty-First Century Fox (NASDAQ:FOXA), Humana (NYSE:HUM), Perrigo (NASDAQ:PRGO), AmerisourceBergen (NYSE:ABC), Hertz (NYSE:HTZ), Community Health (NYSE:CYH), Lamar Advertising (NASDAQ:LAMR), Vodafone (NASDAQ:VOD).
    • 13F
    | Mon, Nov. 14, 4:42 PM | 23 Comments
  • Fri, Nov. 11, 6:47 AM
    • Novartis (NYSE:NVS) upgraded to Buy from Hold with an $85 (15% upside) price target by Argus Research.
    • Humana (NYSE:HUM) upgraded to Overweight from Neutral with a $202 (5% upside) price target by JPMorgan.
    • McKesson (NYSE:MCK) upgraded to Buy from Neutral with a $147 (0% upside) price target by Mizuho Securities.
    • AmerisourceBergen (NYSE:ABC) upgraded to Buy from Neutral by Mizuho Securities. Price target raised to $89 (12% upside) from $84.
    • Healthways (NASDAQ:HWAY) upgraded to Buy from Sell by UBS Global Research. Price target raised to $24 (9% upside) from $22.50.
    • ACADIA Pharmaceuticals (NASDAQ:ACAD) upgraded to Buy from Neutral by Bank of America. Price target lowered to $35 (22% upside) from $39.
    • Biogen (NASDAQ:BIIB) upgraded to Overweight from Neutral with a $335 (3% upside) price target by Piper Jaffray.
    • Juno Therapeutics (NASDAQ:JUNO) upgraded to Neutral from Sell by BTIG Research.
    • Express Scripts (NASDAQ:ESRX) upgraded to Hold from Sell by Deutsche Bank. Price target increased to $70 (7% downside risk) from $69.
    | Fri, Nov. 11, 6:47 AM | 4 Comments
  • Thu, Nov. 10, 9:58 AM
    • AmerisourceBergen (NYSE:ABC) declares $0.365/share quarterly dividend, 7.4% increase from prior dividend of $0.34.
    • Forward yield 1.84%
    • Payable Dec. 5; for shareholders of record Nov. 21; ex-div Nov. 17.
    | Thu, Nov. 10, 9:58 AM | 2 Comments
  • Wed, Nov. 2, 7:54 AM
    • AmerisourceBergen (NYSE:ABC) fiscal Q4 results ($M): Total Revenue: 37,560.6 (+5.9%); Pharmaceutical Distribution: 35,997.1 (+5.9%).
    • Net Income: 145.7 (-59.9%); Non-GAAP Net Income: 297.2 (+11.0%); EPS: 0.64 (-59.0%); Non-GAAP EPS: 1.30 (+12.1%).
    • Consensus view was non-GAAP EPS of $1.23 on revenues of $37.9B; CF Ops (fiscal year): 3,178.5 (-19.0%).
    • Fiscal 2017 Guidance: Revenue Growth: 6.5 - 8.0%; Non-GAAP EPS: $5.63 - 5.88; performance will be stronger in the second half.
    • The board has authorized a new $1B share repurchase program.
    | Wed, Nov. 2, 7:54 AM | 2 Comments
  • Wed, Nov. 2, 6:34 AM
    • AmerisourceBergen (NYSE:ABC): FQ4 EPS of $1.30 beats by $0.07.
    • Revenue of $37.56B (+5.9% Y/Y) misses by $290M.
    • Press Release
    | Wed, Nov. 2, 6:34 AM
  • Tue, Nov. 1, 5:30 PM
  • Fri, Oct. 28, 11:22 AM
    • Drug wholesaler McKesson's (MCK -23.2%) lackluster Q3 numbers and softer guidance due to pricing pressure is weighing on the entire drug supply chain. Competitors AmerisourceBergen (ABC -11.9%) and Cardinal Health (CAH -11.2%) report next week.
    • Representative tickers: (ESRX -4.5%)(CVS -3.9%)(WBA -2.7%)(RAD -0.9%)(UNH +0.1%)
    | Fri, Oct. 28, 11:22 AM | 69 Comments
  • Fri, Oct. 28, 9:20 AM
    | Fri, Oct. 28, 9:20 AM | 24 Comments
  • Fri, Oct. 7, 11:57 AM
    • Ionis Pharmaceuticals (NASDAQ:IONS) upgraded to Outperform from Market Perform by BMO Capital. Price target raised to $48 (42% upside) from $42.
    • Catalyst Pharmaceuticals (NASDAQ:CPRX) upgraded to Overweight from Neutral by Piper Jaffray. Price target raised to $4 (199% upside) from $1.
    • AmerisourceBergen (NYSE:ABC) upgraded to Market Outperform from Market Perform by Avondale Partners.
    • Alnylam Pharmaceuticals (NASDAQ:ALNY) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $40 (14% upside) from $107. Downgraded to Equal Weight from Overweight by Barclays. Price target lowered to $50 (42% upside) from $85. Downgraded to Neutral from Overweight by JPMorgan. Downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $36 (3% upside) from $38.
    • Merrimack Pharmaceuticals (NASDAQ:MACK) downgraded to Neutral from Overweight with a $5.75 (2% upside) price target by JPMorgan.
    • Iradimed (NASDAQ:IRMD) downgraded to Neutral from Buy by Roth Capital. Price target lowered to $11.50 (11% upside) from $28.
    • Trinity Biotech (NASDAQ:TRIB) downgraded to Equal Weight from Overweight by Stephens & Co.
    • Depomed (NASDAQ:DEPO) downgraded to Neutral from Buy by Mizuho Securities.
    • Align Technology (NASDAQ:ALGN) downgraded to Neutral from Overweight with a $96 (8% upside) price target by Baird.
    | Fri, Oct. 7, 11:57 AM | 16 Comments
  • Fri, Oct. 7, 11:48 AM
    • Lexicon Pharmaceuticals (NASDAQ:LXRX) initiated with Buy rating and $26 (38% upside) price target by H.C. Wainwright.
    • Zynerba Pharmaceuticals (NASDAQ:ZYNE) initiated with Buy rating and $22 (54% upside) price target by H.C. Wainwright.
    • Mazor Robotics (NASDAQ:MZOR) initiated with Buy rating and $25 (10% upside) price target by B. Riley.
    • Lipocine (NASDAQ:LPCN) initiated with Buy rating and $25 (350% upside) price target by H.C. Wainwright.
    • TG Therapeutics (NASDAQ:TGTX) initiated with Buy rating and $28 (218% upside) price target by Brean Capital.
    • Immunomedics (NASDAQ:IMMU) initiated with Buy rating and $5.50 (113% upside) price target by Jefferies.
    • AmerisourceBergen (NYSE:ABC) initiated with Neutral rating by UBS.
    • ARIAD Pharmaceuticals (NASDAQ:ARIA) initiated with Buy rating and $22 (65% upside) price target by SunTrust Robinson Humphrey.
    • Amarin (NASDAQ:AMRN) initiated with Buy rating and $6 (92% upside) price target by Cantor Fitzgerald.
    • Corbus Pharmaceuticals (NASDAQ:CRBP) initiated with Buy rating and $17 (94% upside) price target by Cantor Fitzgerald.
    • Heron Therapeutics (NASDAQ:HRTX) initiated with Buy rating and $41 (142% upside) price target by Brean Capital.
    • Zogenix (NASDAQ:ZGNX) initiated with Outperform rating and $17 (64% upside) price target by Leerink Swann.
    • GW Pharmaceuticals (NASDAQ:GWPH) initiated with Outperform rating and $162 (23% upside) price target by Leerink Swann. Initiated with Buy rating and $189 (44% upside) price target by Goldman Sachs.
    • SAGE Therapeutics (NASDAQ:SAGE) initiated with Outperform rating and $68 (57% upside) price target by Leerink Swann.
    • Alexion Pharmaceuticals (NASDAQ:ALXN) initiated with Buy rating and $221 (79% upside) price target by Brean Capital.
    • Axsome Therapeutics (NASDAQ:AXSM) initiated with Buy rating and $20 (136% upside) price target by Brean Capital.
    • Recro Pharma (NASDAQ:REPH) initiated with Buy rating and $21 (156% upside) price target by Brean Capital.
    • SCYNEXIS (NASDAQ:SCYX) initiated with Buy rating and $16 (226% upside) price target by Brean Capital.
    • Sorrento Therapeutics (NASDAQ:SRNE) initiated with Buy rating and $15 (94% upside) price target by Roth Capital.
    • Global Blood Therapeutics (NASDAQ:GBT) initiated with Outperform rating and a $75 - 81 (322% upside from midpoint) target price range by Wells Fargo.
    • Alder Biopharmaceuticals (NASDAQ:ALDR) initiated with Buy rating and $45 (49% upside) price target by Brean Capital.
    | Fri, Oct. 7, 11:48 AM | 8 Comments
  • Thu, Aug. 25, 4:31 PM
    • By mutual agreement, Walgreens Boots Alliance (NASDAQ:WBA) exercises warrants to purchase AmerisourceBergen (NYSE:ABC) common shares that were originally exercisable in March 2017, enabling it to acquire 22,696,912 shares for ~$1.19B. The transaction was funded with cash on hand.
    • WBA now owns 56,854,867 ABC shares representing a stake of 23.9%.
    | Thu, Aug. 25, 4:31 PM | 10 Comments
  • Thu, Aug. 4, 3:45 PM
    • AmerisourceBergen (NYSE:ABC) declares $0.34/share quarterly dividend, in line with previous.
    • Forward yield 1.54%
    • Payable Sept. 6; for shareholders of record Aug. 22; ex-div Aug. 18.
    | Thu, Aug. 4, 3:45 PM
  • Tue, Aug. 2, 9:50 AM
    • AmerisourceBergen (ABC +3.8%) FQ3 results: Revenues: $36,881.7M (+7.7%); Operating Income: $526.6M (+58.3%); Net Income: $349.8M (+63.3%); EPS: $1.56 (+75.3%); Non-GAAP EPS: $1.37 (+14.2%); Quick Assets: $1,865.2M (-13.9%); CF Ops: $1,822M (-34.0%).
    • Fiscal 2016 Guidance: Revenue growth: ~8%; Operating income growth: 5 - 6%; Free cash flow: $1.9B - 2.1B; CAPEX: in the range of $400M.
    • Preliminary Fiscal 2017 Guidance: Non-GAAP EPS growth: 4 - 6%.
    | Tue, Aug. 2, 9:50 AM
  • Tue, Aug. 2, 6:34 AM
    • AmerisourceBergen (NYSE:ABC): FQ3 EPS of $1.37 beats by $0.10.
    • Revenue of $36.88B (+7.7% Y/Y) beats by $170M.
    • Press Release
    | Tue, Aug. 2, 6:34 AM
  • Mon, Aug. 1, 5:30 PM